Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study.
Docampo LI, Basté N, Oliva M, Carral A, Pérez Segura P, Medina-Colmenero A, Cirauqui B, Arrazubi V, Martínez Trufero J, Gutiérrez Calderón V, García Castaño A, Rubió-Casadevall J, Del Barco E, Basterretxea L, Bruixola G, Cabellos RÁ, Flor MJ, Braña I, Caballero J, Martínez J, Lambea J, Perez-Martin X, Montalbán C, Duran M, Mesia R; TTCC (Grupo Español de Tratamiento deTumores de Cabeza y Cuello).
Docampo LI, et al.
Eur J Cancer. 2026 Jun 18;241:116775. doi: 10.1016/j.ejca.2026.116775. Epub 2026 May 6.
Eur J Cancer. 2026.
PMID: 42107346
Free article.
Clinical Trial.
BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who are ineligible for cisplatin have limited treatment options, and the role of chemoimmunotherapy in this population remains unexplored. METHODS: NIVOTAX was a randomized, …
BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who are ineligible for cisplatin …